GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenerx Biopharmaceuticals Inc (OTCPK:RGRX) » Definitions » 5-Year RORE %

Regenerx Biopharmaceuticals (Regenerx Biopharmaceuticals) 5-Year RORE % : 0.00% (As of Mar. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Regenerx Biopharmaceuticals 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Regenerx Biopharmaceuticals's 5-Year RORE % for the quarter that ended in Mar. 2023 was 0.00%.

The industry rank for Regenerx Biopharmaceuticals's 5-Year RORE % or its related term are showing as below:

RGRX's 5-Year RORE % is not ranked *
in the Biotechnology industry.
Industry Median: -7.26
* Ranked among companies with meaningful 5-Year RORE % only.

Regenerx Biopharmaceuticals 5-Year RORE % Historical Data

The historical data trend for Regenerx Biopharmaceuticals's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenerx Biopharmaceuticals 5-Year RORE % Chart

Regenerx Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.80 -53.85 35.68 26.32 -27.51

Regenerx Biopharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.48 -1.69 11.35 -27.51 -19.13

Competitive Comparison of Regenerx Biopharmaceuticals's 5-Year RORE %

For the Biotechnology subindustry, Regenerx Biopharmaceuticals's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenerx Biopharmaceuticals's 5-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenerx Biopharmaceuticals's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Regenerx Biopharmaceuticals's 5-Year RORE % falls into.



Regenerx Biopharmaceuticals 5-Year RORE % Calculation

Regenerx Biopharmaceuticals's 5-Year RORE % for the quarter that ended in Mar. 2023 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -0.903--1.933 )/( -5.385-0 )
=1.03/-5.385
=-19.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2023 and 5-year before.


Regenerx Biopharmaceuticals  (OTCPK:RGRX) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Regenerx Biopharmaceuticals 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Regenerx Biopharmaceuticals's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenerx Biopharmaceuticals (Regenerx Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
15245 Shady Grove Road, Suite 470, Rockville, MD, USA, 20850
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.
Executives
Aptafin S P A other: Member of 10% owner group VIALE SHAKESPEARE 47, ROME L6 00144
Alessandro Noseda director C/O 15245 SHADY GROVE ROAD, SUITE 470, ROCKVILLE MD 20850
S.a. Sinaf 10 percent owner 26 BOULEVARD ROYAL, LUXEMBOURG N4 L-2449
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144
Francesca Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Silvia Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Enrico Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Preta Martina Cavazza 10 percent owner VIA SUDAFRICA 20, ROME L6 00144
Mauro Bove director C/O REGENERX BIOPHARMACEUTICALS, INC., 3 BETHESDA METRO CENTER - SUITE 630, BETHESDA MD 20814
R Don Elsey director 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
J J Finkelstein director
Joseph C Mcnay director 3 BETHESDA METRO CENTER STE 700, C/O REGENERX BIOPHARMACEUTICALS INC, BETHESDA MD 20814
Allan L Goldstein director
Dane R Saglio officer: Chief Financial Officer
Aria Digital 10 percent owner 22ND FL, PARKVIEW TOWER,, 248 JUNGJAIL-RO, BUNDANG-GU,, SEONGNAM-SI, GYEONGGI-DO M4 463-863